Skip to main content
. 2020 Jun 8;35(1):135–142. doi: 10.1111/jdv.16558

Figure 2.

Figure 2

Improvement in skin symptoms as measured by (a) PASI 75, (b) PASI 90 and (c) PASI 100 responses through week 52 (multiple imputation). OR, odds ratio; PASI, Psoriasis Area and Severity Index. *P < 0.0001 vs. ustekinumab 45/90 mg. **P < 0.01 vs. ustekinumab 45/90 mg.